Immune thrombocytopenia (ITP) trials in Germany

In Germany 14 Also abroad 118

13 of 14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Where
Berlin, Dresden, Essen, Frankfurt Am Main, Giessen, Jena, Leipzig
Age
18 years and over
People
60 worldwide
Run by
Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00
Phase 1/2Not yet taking people in Germany
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
Where
Tuebingen
Age
18 years to 80 years
People
36
Run by
University Hospital Tuebingen
See details and how to joinNCT07932262 · EU 2024-519491-60-00
Phase 3Taking people
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Essen, Jena, Mannheim
Age
18 years and over
People
171 worldwide
Run by
Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00
Phase 1Taking people
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Where
Dresden, Erlangen, Goettingen, Luebeck, Rüdersdorf, Tuebingen
Age
18 years and over
People
78 worldwide
Run by
Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00
Phase 3Taking people
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Essen, Jena, Mannheim
Age
18 years and over
People
150 worldwide
Run by
Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00
Phase 3Taking people
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Where
Frankfurt Am Main
Age
18 years to 70 years
People
40 worldwide
Run by
Kedrion S.p.A.
See details and how to joinNCT07059000 · EU 2023-507115-35-00
Phase 1/2Taking people
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Where
Cologne, Dresden, Hanover, Mainz
Age
18 years and over
People
60 worldwide
Run by
CRISPR Therapeutics AG
See details and how to joinNCT07549698
Phase 2/3Taking people
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Where
Berlin, Cologne, Freiburg im Breisgau, Heidelberg
Age
12 years to 17 years
People
24 worldwide
Run by
argenx
See details and how to joinNCT07194850 · EU 2025-521055-23-00
Phase 2Not yet taking people in Germany
Study of Zola-cel (BMS-986353), CD19 NEX-T CAR T Cells in Autoimmune Cytopenia (Breakfree-AiCE)
Where
Erlangen, Magdeburg
Age
18 years and over
People
3 worldwide
Run by
Celgene Corp.
See details and how to join2025-524993-41-00
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Dresden, Erlangen, Goettingen, Rüdersdorf, Tuebingen
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Erlangen, Göttingen, Lübeck, Sachsen, Tübingen
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106
Phase 2Not yet taking people in Germany
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Where
Erlangen, Magdeburg
Age
18 years and over
People
52 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07603557
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Where
Dresden, Essen
Age
18 years and over
People
69 worldwide
Run by
argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00